RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Bernard Arulanandam to Mice, Inbred BALB C

This is a "connection" page, showing publications Bernard Arulanandam has written about Mice, Inbred BALB C.
Connection Strength

2.070
  1. Cunningham AL, Guentzel MN, Yu JJ, Hung CY, Forsthuber TG, Navara CS, Yagita H, Williams IR, Klose KE, Eaves-Pyles TD, Arulanandam BP. M-Cells Contribute to the Entry of an Oral Vaccine but Are Not Essential for the Subsequent Induction of Protective Immunity against Francisella tularensis. PLoS One. 2016; 11(4):e0153402.
    View in: PubMed
    Score: 0.124
  2. Cunningham AL, Dang KM, Yu JJ, Guentzel MN, Heidner HW, Klose KE, Arulanandam BP. Enhancement of vaccine efficacy by expression of a TLR5 ligand in the defined live attenuated Francisella tularensis subsp. novicida strain U112?iglB::fljB. Vaccine. 2014 Sep 08; 32(40):5234-40.
    View in: PubMed
    Score: 0.110
  3. Arulanandam BP, Chetty SL, Yu JJ, Leonard S, Klose K, Seshu J, Cap A, Valdes JJ, Chambers JP. Francisella DnaK inhibits tissue-nonspecific alkaline phosphatase. J Biol Chem. 2012 Oct 26; 287(44):37185-94.
    View in: PubMed
    Score: 0.096
  4. Jupelli M, Murthy AK, Chaganty BK, Guentzel MN, Selby DM, Vasquez MM, Mustafa SB, Henson BM, Seidner SR, Zhong G, Arulanandam BP. Neonatal chlamydial pneumonia induces altered respiratory structure and function lasting into adult life. Lab Invest. 2011 Oct; 91(10):1530-9.
    View in: PubMed
    Score: 0.089
  5. Nallaparaju KC, Yu JJ, Rodriguez SA, Zogaj X, Manam S, Guentzel MN, Seshu J, Murthy AK, Chambers JP, Klose KE, Arulanandam BP. Evasion of IFN-? signaling by Francisella novicida is dependent upon Francisella outer membrane protein C. PLoS One. 2011 Mar 31; 6(3):e18201.
    View in: PubMed
    Score: 0.087
  6. Murthy AK, Li W, Guentzel MN, Zhong G, Arulanandam BP. Vaccination with the defined chlamydial secreted protein CPAF induces robust protection against female infertility following repeated genital chlamydial challenge. Vaccine. 2011 Mar 21; 29(14):2519-22.
    View in: PubMed
    Score: 0.086
  7. Rodriguez AR, Yu JJ, Murthy AK, Guentzel MN, Klose KE, Forsthuber TG, Chambers JP, Berton MT, Arulanandam BP. Mast cell/IL-4 control of Francisella tularensis replication and host cell death is associated with increased ATP production and phagosomal acidification. Mucosal Immunol. 2011 Mar; 4(2):217-26.
    View in: PubMed
    Score: 0.084
  8. Li W, Murthy AK, Guentzel MN, Chambers JP, Forsthuber TG, Seshu J, Zhong G, Arulanandam BP. Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge. Infect Immun. 2010 Sep; 78(9):3942-9.
    View in: PubMed
    Score: 0.083
  9. Jupelli M, Selby DM, Guentzel MN, Chambers JP, Forsthuber TG, Zhong G, Murthy AK, Arulanandam BP. The contribution of interleukin-12/interferon-gamma axis in protection against neonatal pulmonary Chlamydia muridarum challenge. J Interferon Cytokine Res. 2010 Jun; 30(6):407-15.
    View in: PubMed
    Score: 0.082
  10. Chaganty BK, Murthy AK, Evani SJ, Li W, Guentzel MN, Chambers JP, Zhong G, Arulanandam BP. Heat denatured enzymatically inactive recombinant chlamydial protease-like activity factor induces robust protective immunity against genital chlamydial challenge. Vaccine. 2010 Mar 08; 28(11):2323-9.
    View in: PubMed
    Score: 0.080
  11. Cong Y, Yu JJ, Guentzel MN, Berton MT, Seshu J, Klose KE, Arulanandam BP. Vaccination with a defined Francisella tularensis subsp. novicida pathogenicity island mutant (DeltaiglB) induces protective immunity against homotypic and heterotypic challenge. Vaccine. 2009 Sep 18; 27(41):5554-61.
    View in: PubMed
    Score: 0.078
  12. Ray HJ, Cong Y, Murthy AK, Selby DM, Klose KE, Barker JR, Guentzel MN, Arulanandam BP. Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A. Clin Vaccine Immunol. 2009 Apr; 16(4):444-52.
    View in: PubMed
    Score: 0.075
  13. Ketavarapu JM, Rodriguez AR, Yu JJ, Cong Y, Murthy AK, Forsthuber TG, Guentzel MN, Klose KE, Berton MT, Arulanandam BP. Mast cells inhibit intramacrophage Francisella tularensis replication via contact and secreted products including IL-4. Proc Natl Acad Sci U S A. 2008 Jul 08; 105(27):9313-8.
    View in: PubMed
    Score: 0.072
  14. Powell HJ, Cong Y, Yu JJ, Guentzel MN, Berton MT, Klose KE, Murthy AK, Arulanandam BP. CD4+ T cells are required during priming but not the effector phase of antibody-mediated IFN-gamma-dependent protective immunity against pulmonary Francisella novicida infection. Immunol Cell Biol. 2008 Aug-Sep; 86(6):515-22.
    View in: PubMed
    Score: 0.071
  15. Jupelli M, Guentzel MN, Meier PA, Zhong G, Murthy AK, Arulanandam BP. Endogenous IFN-gamma production is induced and required for protective immunity against pulmonary chlamydial infection in neonatal mice. J Immunol. 2008 Mar 15; 180(6):4148-55.
    View in: PubMed
    Score: 0.071
  16. Li W, Murthy AK, Guentzel MN, Seshu J, Forsthuber TG, Zhong G, Arulanandam BP. Antigen-specific CD4+ T cells produce sufficient IFN-gamma to mediate robust protective immunity against genital Chlamydia muridarum infection. J Immunol. 2008 Mar 01; 180(5):3375-82.
    View in: PubMed
    Score: 0.071
  17. Yu JJ, Raulie EK, Murthy AK, Guentzel MN, Klose KE, Arulanandam BP. The presence of infectious extracellular Francisella tularensis subsp. novicida in murine plasma after pulmonary challenge. Eur J Clin Microbiol Infect Dis. 2008 Apr; 27(4):323-5.
    View in: PubMed
    Score: 0.070
  18. Li W, Guentzel MN, Seshu J, Zhong G, Murthy AK, Arulanandam BP. Induction of cross-serovar protection against genital chlamydial infection by a targeted multisubunit vaccination approach. Clin Vaccine Immunol. 2007 Dec; 14(12):1537-44.
    View in: PubMed
    Score: 0.069
  19. Cong Y, Jupelli M, Guentzel MN, Zhong G, Murthy AK, Arulanandam BP. Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection. Vaccine. 2007 May 10; 25(19):3773-80.
    View in: PubMed
    Score: 0.066
  20. Murthy AK, Chambers JP, Meier PA, Zhong G, Arulanandam BP. Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production. Infect Immun. 2007 Feb; 75(2):666-76.
    View in: PubMed
    Score: 0.065
  21. Pammit MA, Raulie EK, Lauriano CM, Klose KE, Arulanandam BP. Intranasal vaccination with a defined attenuated Francisella novicida strain induces gamma interferon-dependent antibody-mediated protection against tularemia. Infect Immun. 2006 Apr; 74(4):2063-71.
    View in: PubMed
    Score: 0.062
  22. Pammit MA, Budhavarapu VN, Raulie EK, Klose KE, Teale JM, Arulanandam BP. Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection. Antimicrob Agents Chemother. 2004 Dec; 48(12):4513-9.
    View in: PubMed
    Score: 0.056
  23. Arulanandam BP, Mittler JN, Lee WT, O'Toole M, Metzger DW. Neonatal administration of IL-12 enhances the protective efficacy of antiviral vaccines. J Immunol. 2000 Apr 01; 164(7):3698-704.
    View in: PubMed
    Score: 0.041
  24. Arulanandam BP, O'Toole M, Metzger DW. Intranasal interleukin-12 is a powerful adjuvant for protective mucosal immunity. J Infect Dis. 1999 Oct; 180(4):940-9.
    View in: PubMed
    Score: 0.039
  25. Holloway AJ, Yu J, Arulanandam BP, Milligan GN, Eaves-Pyles TD. Combination of Cystatins 9 and C Modulates Serum Biomarkers Associated with Inflammation and Provides Prophylactic as Well as Long-Term Protection against Multidrug-Resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2019 05; 63(5).
    View in: PubMed
    Score: 0.038
  26. Arulanandam BP, Metzger DW. Modulation of mucosal and systemic immunity by intranasal interleukin 12 delivery. Vaccine. 1999 Jan 21; 17(3):252-60.
    View in: PubMed
    Score: 0.038
  27. Arulanandam BP, Van Cleave VH, Metzger DW. IL-12 is a potent neonatal vaccine adjuvant. Eur J Immunol. 1999 01; 29(1):256-64.
    View in: PubMed
    Score: 0.037
  28. Holloway AJ, Yu J, Arulanandam BP, Hoskinson SM, Eaves-Pyles T. Cystatins 9 and C as a Novel Immunotherapy Treatment That Protects against Multidrug-Resistant New Delhi Metallo-Beta-Lactamase-1-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2018 03; 62(3).
    View in: PubMed
    Score: 0.035
  29. Campbell J, Huang Y, Liu Y, Schenken R, Arulanandam B, Zhong G. Bioluminescence imaging of Chlamydia muridarum ascending infection in mice. PLoS One. 2014; 9(7):e101634.
    View in: PubMed
    Score: 0.027
  30. Eaves-Pyles T, Patel J, Arigi E, Cong Y, Cao A, Garg N, Dhiman M, Pyles RB, Arulanandam B, Miller AL, Popov VL, Soong L, Carlsen ED, Coletta C, Szabo C, Almeida IC. Immunomodulatory and antibacterial effects of cystatin 9 against Francisella tularensis. Mol Med. 2013 Aug 28; 19:263-75.
    View in: PubMed
    Score: 0.026
  31. Barker JR, Chong A, Wehrly TD, Yu JJ, Rodriguez SA, Liu J, Celli J, Arulanandam BP, Klose KE. The Francisella tularensis pathogenicity island encodes a secretion system that is required for phagosome escape and virulence. Mol Microbiol. 2009 Dec; 74(6):1459-70.
    View in: PubMed
    Score: 0.020
  32. Buchanan RM, Briles DE, Arulanandam BP, Westerink MA, Raeder RH, Metzger DW. IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines. Vaccine. 2001 Feb 28; 19(15-16):2020-8.
    View in: PubMed
    Score: 0.011
  33. Buchanan RM, Arulanandam BP, Metzger DW. IL-12 enhances antibody responses to T-independent polysaccharide vaccines in the absence of T and NK cells. J Immunol. 1998 Nov 15; 161(10):5525-33.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support